Wall Street closes at a record for the first time since end of January
Cosmos Health Inc. (COSM) reported record annual revenue of $65.3 million for the year ended December 31, 2025, representing a 20% increase from $54.4 million in 2024, according to a company press release.
The healthcare group’s gross profit increased 83% to $7.9 million compared to $4.3 million in the prior year. Gross margin expanded to 12.10% from 7.92%, an improvement of 418 basis points. Cash and cash equivalents increased to $3.5 million from $315,105 at the end of 2024.
The company reported a net loss of $19.1 million, compared to $16.2 million in 2024. Adjusted net loss per share improved to $0.12 from $0.65 in the previous year. Total operating expenses increased to $24.6 million from $19.9 million, reflecting strategic investments in personnel and growth initiatives.
Cosmos Health secured long-term contract manufacturing agreements representing over 12 million units through its Cana Laboratories division. The company expanded its Sky Premium Life product portfolio by 60 SKUs and secured purchase orders for over 300,000 units across new markets.
The company obtained a $300 million financing facility to launch a digital asset treasury strategy and invested $2 million in Ethereum. Chief Executive Officer Greg Siokas acquired more than 3.3 million shares during 2025.
Cosmos Health launched operations in the United States with NOOR Collagen, which the company projects will generate over $12 million in revenue within 12 months at approximately 75% gross margins. The company also expanded Sky Premium Life distribution into Albania, Kuwait, and Oman.
Total assets increased to $65.5 million from $54.3 million at the end of 2024. The company secured buy-out rights and exclusive licensing for two patented anticancer drugs valued at over $24.5 million, targeting prostate, ovarian, and colorectal cancers.